中國Accelerated Patent ExaminationChina Patent OfficeCNIPAHong KongInventionsPrioritized Examination
2023年1月4日

BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

by
張佩雯女士
車李曉芸女士

New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To be eligible, the patent application must be:

  1. an invention application filed directly in China or via national phase entry into China in the substantive examination stage;
  2. filed electronically;
  3. the invention belongs to a qualified technical field, such as internet, big data, cloud computing, biotechnology, environment protection, high-end technology manufacturing, new materials, energy conservation, and more—check out this document (Chinese only) to see the eligible IPC codes; and
  4. the applicant or at least one co-applicant must be (1) a Hong Kong permanent resident or (2) a company established under Companies Ordinance in Hong Kong or a legal entity or organization of other types in Hong Kong.

To request a prioritized examination, the applicant will need to submit a request form along with other required documents to the CNIPA at one of the representative offices in Guangdong or Shenzhen, by mail or in person. Of particular note, applicants must submit information about the existing technology in the field, i.e., known prior art, not unlike an Information Disclosure Statement (IDS) in the US. The applicant must appoint an agency to file the request for prioritized examination unless they have a permanent residence or business office in Mainland China.

Additional Notes:

  • Same Day Invention + UM Applications will generally not receive prioritized examination
  • All foreign language materials must be translated into Chinese
  • There is no charge for this service
  • Restrictions may apply

EIP Comments

This ability to get prioritized examination is great news for Hong Kong permanent residents and Hong Kong companies. Hong Kong could become a very strategic location for international businesses thinking of setting up an office in Asia, especially if being able to get Chinese patents granted quickly is important. International companies can also consider partnering with Hong Kong entities, since co-applicants including a Hong Kong applicant can also enjoy this new pilot program.

If you think you may be eligible for this “fast track” route and would like some help, please feel free to contact us. Our Shenzhen entity Eagle IP (Shenzhen) is a registered Chinese patent agency and we can assist with applications under this pilot program.

Official details (Chinese only) can be found here: https://www.cnipa.gov.cn/art/2022/12/23/art_53_180967.html

For more details about prioritized examination, feel free to send us an email at [email protected].

Eagle IP is a top-tier boutique patent firm with a unique mix of experienced US and Chinese patent professionals with significant cross-border knowledge and experience. Our technically expertise covers wide range of technologies including, but not limited, to life sciences, biotechnology, medicine, pharmaceuticals, material and environmental science, chemistry and consumer electronics. We have years of experiences in drafting and prosecuting patent applications involving biological deposits, sequence listings, small and large molecules, drug discovery and development, material science, software and engineering, and many others.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

2019年11月21日
Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]

Breaking: China Released New Implementation Measures for the New Patent Linkage System

2021年7月14日
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]

Obviousness: can features from different categories of products be combined to invalidate a design patent?

2025年9月18日
Introduction “I have a tank, I have a gun—boom! Tank gun?” Each year the CNIPA releases a list of Top Ten Patent Re-examination and Invalidation Cases. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Over the next several months we will be highlighting many […]

我們過去活動

Top crossarrow-right